Condition: Solid Tumors · Sponsor: Incyte Corporation
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital | Phoenix, Arizona, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| UCLA Healthcare Hematology-Oncology | Santa Monica, California, United States | Recruiting |
| Sarah Cannon Research Institue At Healthone | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| Weill Cornell Medicine | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Jefferson University Hospitals | Philadelphia, Pennsylvania, United States | Recruiting |
| Scri Oncology Partners | Nashville, Tennessee, United States | Recruiting |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06179160